Can you take Amphotericin b lipid complex with Lansoprazole?

amphotericin B lipid complex has a moderate potential interaction with Anemia.

Amphotericin B lipid complex may depress red blood cell production and occasionally causes a normocytic, normochromic anemia. A 4% incidence was reported during clinical trials. Although the anemia is generally well tolerated and reverses completely after discontinuation of therapy, it may be problematic in patients with preexisting anemia. Therapy with amphotericin B lipid complex should be administered cautiously in anemic patients. Frequent blood counts and hematocrit levels are recommended.

Lansoprazole has a major potential interaction with Diarrhea.

Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve. It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. C. difficile produces toxins A and B, which contribute to the development of CDAD. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

amphotericin B lipid complex has a moderate potential interaction with Hyperkalemia.

Amphotericin B lipid complex is substantially less nephrotoxic than traditional amphotericin B but may still cause hypo- and hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be monitored in all patients receiving therapy with amphotericin B lipid complex but particularly closely in patients with preexisting electrolyte abnormalities. Mineral and electrolyte supplementation may likely be required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances.

amphotericin B lipid complex has a moderate potential interaction with Hypocalcemia.

Amphotericin B lipid complex is substantially less nephrotoxic than traditional amphotericin B but may still cause hypo- and hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be monitored in all patients receiving therapy with amphotericin B lipid complex but particularly closely in patients with preexisting electrolyte abnormalities. Mineral and electrolyte supplementation may likely be required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances.

amphotericin B lipid complex has a moderate potential interaction with Hypokalemia.

Amphotericin B lipid complex is substantially less nephrotoxic than traditional amphotericin B but may still cause hypo- and hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be monitored in all patients receiving therapy with amphotericin B lipid complex but particularly closely in patients with preexisting electrolyte abnormalities. Mineral and electrolyte supplementation may likely be required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances.

Lansoprazole has a moderate potential interaction with Liver Disease.

Lansoprazole is primarily metabolized by the liver. Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.

amphotericin B lipid complex has a moderate potential interaction with Magnesium Imbalance.

Amphotericin B lipid complex is substantially less nephrotoxic than traditional amphotericin B but may still cause hypo- and hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be monitored in all patients receiving therapy with amphotericin B lipid complex but particularly closely in patients with preexisting electrolyte abnormalities. Mineral and electrolyte supplementation may likely be required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances.

Lansoprazole has a moderate potential interaction with Magnesium Imbalance.

Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy. Serious adverse events can include tetany, seizures, and arrhythmias. Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics). Regular monitoring is recommended.

Lansoprazole has a moderate potential interaction with Osteoporosis.

Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine. The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.

Lansoprazole has a major potential interaction with Pseudomembranous Colitis.

Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve. It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. C. difficile produces toxins A and B, which contribute to the development of CDAD. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

amphotericin B lipid complex has a moderate potential interaction with Renal Dysfunction.

Amphotericin B lipid complex is substantially less nephrotoxic than traditional amphotericin B but may still cause decreased renal function and abnormalities such as hypo- and hyperkalemia, hypomagnesemia, and renal tubular acidosis. Renal function should be monitored in all patients receiving therapy with amphotericin B lipid complex but particularly closely in patients with preexisting renal impairment. Serum creatinine, BUN, potassium and magnesium levels should be evaluated regularly, and dosing adjusted or discontinued if necessary. Hydration with normal saline may decrease the risk for nephrotoxicity. In addition, administration of alkali medication may help to prevent renal tubular acidosis.